Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar i disorder: A post hoc analysis of pooled data from short- and long-term aripiprazole trials

John M. Kane, Thomas Re Barnes, Christoph U. Correll, Gary Sachs, Peter F Buckley, James Eudicone, Robert McQuade, Quynh Van Tran, Andrei Pikalov, Sheila Assunção-Talbott

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The objective of this article is to assess the clinical characteristics of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder receiving aripiprazole, haloperidol, olanzapine, or placebo. We conducted post hoc analyses of pooled safety data from trials in patients with schizophrenia, schizoaffective disorder, and bipolar I disorder. Outcome measures included the incidence of akathisia, time to onset, duration, severity, and discontinuation due to akathisia, concomitant use of benzodiazepines and/or anticholinergics, Barnes Akathisia Rating Scale (BARS) scores, and the correlation between antipsychotic efficacy and akathisia. The results for schizophrenia and schizoaffective disorder were as follows: akathisia in 9% of aripiprazole- and 6% of placebo-treated patients; 12.5% of aripiprazole- versus 24% of haloperidol-treated patients; 11% of aripiprazole- versus 6% of olanzapine-treated patients. Bipolar I disorder: akathisia in 18% of aripiprazole- and 5% of placebo-treated patients. The clinical characteristics of akathisia were similar between each data set, regardless of disease. Akathisia was generally mild-to-moderate in severity. Discontinuation due to akathisia was low in both the schizophrenia trials (aripiprazole 0.3%; placebo 0%; aripiprazole 0.9%; haloperidol 2.3%; aripiprazole 1.2%; olanzapine 0.2%) and the bipolar trials (aripiprazole 2.3%; placebo 0%). Treatment-emergent akathisia was not associated with a poorer clinical response. In conclusion, akathisia with aripiprazole occurred early in treatment, was mild-to-moderate in severity, led to few study discontinuations, and did not compromise therapeutic efficacy.

Original languageEnglish (US)
Pages (from-to)1019-1029
Number of pages11
JournalJournal of Psychopharmacology
Volume24
Issue number7
DOIs
StatePublished - Jul 1 2010

Fingerprint

Psychomotor Agitation
Bipolar Disorder
Psychotic Disorders
Schizophrenia
olanzapine
Placebos
Haloperidol
Aripiprazole
Cholinergic Antagonists
Benzodiazepines
Antipsychotic Agents
Therapeutics

Keywords

  • Akathisia
  • Aripiprazole
  • Bipolar I disorder
  • Haloperidol
  • Olanzapine
  • Schizoaffective disorder
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar i disorder : A post hoc analysis of pooled data from short- and long-term aripiprazole trials. / Kane, John M.; Barnes, Thomas Re; Correll, Christoph U.; Sachs, Gary; Buckley, Peter F; Eudicone, James; McQuade, Robert; Tran, Quynh Van; Pikalov, Andrei; Assunção-Talbott, Sheila.

In: Journal of Psychopharmacology, Vol. 24, No. 7, 01.07.2010, p. 1019-1029.

Research output: Contribution to journalArticle

Kane, JM, Barnes, TR, Correll, CU, Sachs, G, Buckley, PF, Eudicone, J, McQuade, R, Tran, QV, Pikalov, A & Assunção-Talbott, S 2010, 'Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar i disorder: A post hoc analysis of pooled data from short- and long-term aripiprazole trials', Journal of Psychopharmacology, vol. 24, no. 7, pp. 1019-1029. https://doi.org/10.1177/0269881109348157
Kane, John M. ; Barnes, Thomas Re ; Correll, Christoph U. ; Sachs, Gary ; Buckley, Peter F ; Eudicone, James ; McQuade, Robert ; Tran, Quynh Van ; Pikalov, Andrei ; Assunção-Talbott, Sheila. / Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar i disorder : A post hoc analysis of pooled data from short- and long-term aripiprazole trials. In: Journal of Psychopharmacology. 2010 ; Vol. 24, No. 7. pp. 1019-1029.
@article{c835495f85a740a592b31a5ecdc29e94,
title = "Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar i disorder: A post hoc analysis of pooled data from short- and long-term aripiprazole trials",
abstract = "The objective of this article is to assess the clinical characteristics of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder receiving aripiprazole, haloperidol, olanzapine, or placebo. We conducted post hoc analyses of pooled safety data from trials in patients with schizophrenia, schizoaffective disorder, and bipolar I disorder. Outcome measures included the incidence of akathisia, time to onset, duration, severity, and discontinuation due to akathisia, concomitant use of benzodiazepines and/or anticholinergics, Barnes Akathisia Rating Scale (BARS) scores, and the correlation between antipsychotic efficacy and akathisia. The results for schizophrenia and schizoaffective disorder were as follows: akathisia in 9{\%} of aripiprazole- and 6{\%} of placebo-treated patients; 12.5{\%} of aripiprazole- versus 24{\%} of haloperidol-treated patients; 11{\%} of aripiprazole- versus 6{\%} of olanzapine-treated patients. Bipolar I disorder: akathisia in 18{\%} of aripiprazole- and 5{\%} of placebo-treated patients. The clinical characteristics of akathisia were similar between each data set, regardless of disease. Akathisia was generally mild-to-moderate in severity. Discontinuation due to akathisia was low in both the schizophrenia trials (aripiprazole 0.3{\%}; placebo 0{\%}; aripiprazole 0.9{\%}; haloperidol 2.3{\%}; aripiprazole 1.2{\%}; olanzapine 0.2{\%}) and the bipolar trials (aripiprazole 2.3{\%}; placebo 0{\%}). Treatment-emergent akathisia was not associated with a poorer clinical response. In conclusion, akathisia with aripiprazole occurred early in treatment, was mild-to-moderate in severity, led to few study discontinuations, and did not compromise therapeutic efficacy.",
keywords = "Akathisia, Aripiprazole, Bipolar I disorder, Haloperidol, Olanzapine, Schizoaffective disorder, Schizophrenia",
author = "Kane, {John M.} and Barnes, {Thomas Re} and Correll, {Christoph U.} and Gary Sachs and Buckley, {Peter F} and James Eudicone and Robert McQuade and Tran, {Quynh Van} and Andrei Pikalov and Sheila Assun{\cc}{\~a}o-Talbott",
year = "2010",
month = "7",
day = "1",
doi = "10.1177/0269881109348157",
language = "English (US)",
volume = "24",
pages = "1019--1029",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar i disorder

T2 - A post hoc analysis of pooled data from short- and long-term aripiprazole trials

AU - Kane, John M.

AU - Barnes, Thomas Re

AU - Correll, Christoph U.

AU - Sachs, Gary

AU - Buckley, Peter F

AU - Eudicone, James

AU - McQuade, Robert

AU - Tran, Quynh Van

AU - Pikalov, Andrei

AU - Assunção-Talbott, Sheila

PY - 2010/7/1

Y1 - 2010/7/1

N2 - The objective of this article is to assess the clinical characteristics of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder receiving aripiprazole, haloperidol, olanzapine, or placebo. We conducted post hoc analyses of pooled safety data from trials in patients with schizophrenia, schizoaffective disorder, and bipolar I disorder. Outcome measures included the incidence of akathisia, time to onset, duration, severity, and discontinuation due to akathisia, concomitant use of benzodiazepines and/or anticholinergics, Barnes Akathisia Rating Scale (BARS) scores, and the correlation between antipsychotic efficacy and akathisia. The results for schizophrenia and schizoaffective disorder were as follows: akathisia in 9% of aripiprazole- and 6% of placebo-treated patients; 12.5% of aripiprazole- versus 24% of haloperidol-treated patients; 11% of aripiprazole- versus 6% of olanzapine-treated patients. Bipolar I disorder: akathisia in 18% of aripiprazole- and 5% of placebo-treated patients. The clinical characteristics of akathisia were similar between each data set, regardless of disease. Akathisia was generally mild-to-moderate in severity. Discontinuation due to akathisia was low in both the schizophrenia trials (aripiprazole 0.3%; placebo 0%; aripiprazole 0.9%; haloperidol 2.3%; aripiprazole 1.2%; olanzapine 0.2%) and the bipolar trials (aripiprazole 2.3%; placebo 0%). Treatment-emergent akathisia was not associated with a poorer clinical response. In conclusion, akathisia with aripiprazole occurred early in treatment, was mild-to-moderate in severity, led to few study discontinuations, and did not compromise therapeutic efficacy.

AB - The objective of this article is to assess the clinical characteristics of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder receiving aripiprazole, haloperidol, olanzapine, or placebo. We conducted post hoc analyses of pooled safety data from trials in patients with schizophrenia, schizoaffective disorder, and bipolar I disorder. Outcome measures included the incidence of akathisia, time to onset, duration, severity, and discontinuation due to akathisia, concomitant use of benzodiazepines and/or anticholinergics, Barnes Akathisia Rating Scale (BARS) scores, and the correlation between antipsychotic efficacy and akathisia. The results for schizophrenia and schizoaffective disorder were as follows: akathisia in 9% of aripiprazole- and 6% of placebo-treated patients; 12.5% of aripiprazole- versus 24% of haloperidol-treated patients; 11% of aripiprazole- versus 6% of olanzapine-treated patients. Bipolar I disorder: akathisia in 18% of aripiprazole- and 5% of placebo-treated patients. The clinical characteristics of akathisia were similar between each data set, regardless of disease. Akathisia was generally mild-to-moderate in severity. Discontinuation due to akathisia was low in both the schizophrenia trials (aripiprazole 0.3%; placebo 0%; aripiprazole 0.9%; haloperidol 2.3%; aripiprazole 1.2%; olanzapine 0.2%) and the bipolar trials (aripiprazole 2.3%; placebo 0%). Treatment-emergent akathisia was not associated with a poorer clinical response. In conclusion, akathisia with aripiprazole occurred early in treatment, was mild-to-moderate in severity, led to few study discontinuations, and did not compromise therapeutic efficacy.

KW - Akathisia

KW - Aripiprazole

KW - Bipolar I disorder

KW - Haloperidol

KW - Olanzapine

KW - Schizoaffective disorder

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=77951165069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951165069&partnerID=8YFLogxK

U2 - 10.1177/0269881109348157

DO - 10.1177/0269881109348157

M3 - Article

C2 - 20008446

AN - SCOPUS:77951165069

VL - 24

SP - 1019

EP - 1029

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 7

ER -